Stockscreener 앱 받기
0.3065
12.72%
0.0315
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Medicus Pharma reports dose response data from skin cancer study By Investing.com - Investing.com Canada
Skin cancer study points to higher-dose winner with 55% response - Stock Titan
Medicus Pharma Announces Results from Pre-Specified - GlobeNewswire
EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study - Benzinga
Medicus Pharma Meets Lawmakers to Advance SkinJect Program - MyChesCo
Medicus reports Phase 2 basal cell carcinoma trial results By Investing.com - Investing.com India
MDCX Forecast, Price Target & Analyst Ratings | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma on Bloomberg World - Public Opinion
Medicus Pharma 2025 Executive Compensation, Board Governance, and Equity Incentive Plan Overview - Minichart
Medicus Pharma (Nasdaq: MDCX) details board structure and leadership pay - Stock Titan
Exclusive: Medicus Pharma refines trial design to cut costs, accelerate development for enlarged prostate patients - MSN
MDCXW Price History for Medicus Pharma Ltd WT Stock - Barchart.com
MDCX Technical Analysis | Trend, Signals & Chart Patterns | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome - Yahoo! Finance Canada
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill - The Manila Times
Medicus Pharma to acquire Antev for $75M in share exchange transaction - MSN
Medicus Pharma prices $7 million share offering - MSN
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global - ACCESS Newswire
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ - marketscreener.com
Balancing Pipeline Potential and Funding Risk: Justifying a Buy Rating on Medicus Despite Extended Timelines - TipRanks
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - Wisconsin Farmer
Medicus Pharma (NASDAQ: MDCX) ups ATM to $50M; Nasdaq bid‑price notice - Stock Titan
Medicus Pharma receives Nasdaq notice for minimum bid price non-compliance - Investing.com UK
Medicus Pharma Expands ATM Equity Program for Funding - TipRanks
Medicus Pharma Upsizes ATM Program to $50 Million With Maxim Group and Yorkville Securities - TradingView
Nasdaq warns Medicus Pharma (NASDAQ: MDCX) on $1 bid price rule - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Medicus Pharma advances Skinject in rare disease – ICYMI - Proactive financial news
Medicus Pharma to acquire Antev - MSN
Medicus Pharma Ltd may offer and sell common shares up to $50 million aggregate through agents - marketscreener.com
Medicus Pharma Ltd May Offer And Sell Common Shares Up To $50 Million Aggregate Through Agents - TradingView
MDCX (NASDAQ: MDCX) increases equity ATM to $50,000,000 with Maxim, Yorkville - Stock Titan
ICYMI: Medicus Pharma Seeks FDA Orphan Drug Designation for SkinJect in Gorlin Syndrome - Dermatology Times
3 Stocks To BUY NOW In March 2026 (wLdea9HGKw) - Fathom Journal
Medicus Pharma (MDCX) Stock: Important Info (Institutional Selling) 2026-04-22Popular Trader Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Is Medicus Pharma (MDCX) stock forming a breakout | Q4 2025: Earnings UnderperformNetwork Effect - Xã Thanh Hà
Medicus Pharma Submits Orphan Drug Application for SkinJect - MyChesCo
Analysts’ Top Healthcare Picks: Surrozen (SRZN), Establishment Labs Holdings (ESTA) - The Globe and Mail
Exclusive: Penny stock Medicus Pharma findings support potential in women's health pipeline - MSN
Medicus Pharma (MDCX) asks shareholders to approve up to 50-for-1 reverse split - Stock Titan
Medicus Pharma to Present Phase 1 Data on Teverelix at AACE 2026 - MyChesCo
Medicus Pharma Is Maintained at Buy by D. Boral Capital - Moomoo
Medicus Pharma files Orphan Drug application for SkinJect in rare skin Cancer indication - Proactive financial news
0.84%
자본화:
|
볼륨(24시간):